age-related muscle loss sarcopenia
Conditions
Interventions
One group (n=12) will consume a test beverage of 350 mL containing 20 g of
intrinsically labeled casein, and the other group (n=12) will consume a
beverage of the same volume containing 20 g of case
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Healthy males * Age between 55 and 85 * BMI
Exclusion criteria
Exclusion criteria: * Glucose intolerance * Milk and/or fat intolerance * Smoking * Diagnosed GI tract diseases * Arthritic conditions * A history of neuromuscular problems * Any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications). * Use of anticoagulants * Participation in exercise program * Hypertention, high blood pressure above 140/90 mmHg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is muscle protein synthesis (MPS) rate. In order to determine the MPS, the following parameters will be measured in blood and muscle tissue: * Plasma phenylalanine concentration (expressed as *mol/L) * Plasma enrichment of L-[ ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine (expressed as mole percent excess, MPE) * Muscle protein bound enrichment of L-[ ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine (expressed as MPE) * L-[ ring-2H5]phenylalanine and L-[1-13C]-phenylalanine enrichment of the muscle free amino acid pool (expressed as MPE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include whole-body protein turnover, and protein digestion and absorption kinetics. The following parameters will be calculated: * Total rate of phenylalanine appearance and disappearance (= protein turnover) * Exogenous phenylalanine rate of appearance * Endogenous phenylalanine rate of appearance (=protein breakdown) * Plasma availability of phenylalanine | — |
Countries
Netherlands
Outcome results
None listed